Overview

A Phase 2 Placebo Controlled, Clinical Trial Designed to Assess the Efficacy, Safety and Dose Response Characterisation of STS01 for the Treatment of Mild-moderate Alopecia Areata (AA)

Status:
COMPLETED
Trial end date:
2024-04-01
Target enrollment:
Participant gender:
Summary
A Phase 2 double-blind, multi-site, placebo-controlled, parallel-group design to assess the efficacy, safety and dose-response characterisation of STS-01 for the treatment of mild- moderate alopecia areata.
Phase:
PHASE2
Details
Lead Sponsor:
Soterios Ltd